

# Tame the Flame as soon as they're Lame



**Act Fast. Use First: Only Synovetin OA<sup>®</sup> treats the inflammation that fuels osteoarthritis pain and progression**

  
**Synovetin OA**

Long-lasting Relief

[synovetin.com](http://synovetin.com)


# In arthritis, synovial inflammation is the enemy burning within

It's literally a disease of inflammation, the underlying "fiery" source of the pain that robs dogs of their mobility, quality of life, and joyful companionship.



ARTHR - ITIS  
↓ ↓  
JOINT INFLAMMATION

SYNOV - ITIS  
↓ ↓  
SYNOVIAL INFLAMMATION




- Arthritis is driven by synovitis (inflammation of the synovium) which leads to over production of macrophages and synoviocytes
  - Drives the release of pro-inflammatory mediators that destroy cartilage
  - Creates a vicious cycle of ongoing inflammation, pain, and cartilage destruction
- The MOST Study<sup>a</sup> found a 2.7-fold greater risk (p=0.002) of cartilage loss in subjects with synovitis, indicating its chondro-destructive effects<sup>1</sup>

<sup>a</sup>MOST, Multicenter Osteoarthritis Study  
Evaluated 514 human subjects with MRI-detected effusion synovitis of the knee over 30 months

## Treating arthritis must involve treating inflammation in the joint

- If only the pain is treated but not the inflammation driving the disease, progression proceeds unchecked and can be debilitating
- Breaking the vicious cycle of inflammation is key to reducing joint damage and chronic pain

## IF UNTREATED, INFLAMMATION INSIDE THE JOINT RESULTS IN ARTHRITIS PROGRESSION




THE VICIOUS CYCLE OF INFLAMMATION LEADS TO WORSENING ARTHRITIS

Early intervention that targets synovitis mitigates the cytokine cascade that leads to joint destruction.<sup>2,3</sup>

# Only Synovetin OA targets the inflammation that causes OA pain and progression

## Synovetin OA is a veterinary device that goes beyond NSAIDs and anti-NGFs which primarily mask pain signals<sup>4-6</sup>


- Synovetin OA is comprised of microscopic radiotherapeutic particles that are injected directly into the joint
- Once in the joint, these particles safely reduce the inflammation that's causing pain, destroying cartilage, and driving OA disease progression



## Up to 1 full year of relief with just 1 simple, safe treatment

Compared with other canine OA treatments that require daily or monthly dosing, Synovetin OA is a convenient option that also eliminates compliance problems.

### SYNOVETIN OA®—LONGEST-LASTING PAIN RELIEF





Synovetin OA is a first-line choice best used in early OA management to relieve the pain and help preserve the health of the joint.

# Success demonstrated in published clinical studies


## Peer reviewed, published data prove up to 1 year of relief with just 1 treatment<sup>4-6</sup>

Synovetin OA provides increasing pain relief and improved mobility over a year, yet with no active tin-117m remaining in the joint.




\*Overall treatment success based on a composite of force plate, Canine Brief Pain Index (CBPI), and clinician assessments for the label dose.


## Exceptionally safe with no systemic side effects—so you can treat with confidence<sup>4,7</sup>




No effect on bone, cartilage, ligaments, or other joint structures



No systemic distribution with no systemic or adverse events



CBC and serum chemistry values remained within normal limits



Serial blood, urine, and fecal counts show >99.1% is retained in the injected joint

Intra-articular injection with Synovetin OA is minimally invasive and safe for treated dogs, other pets, and their families.

# Tin-117m, the active component in Synovetin OA— Preclinical and clinical evidence of potential disease modification in mammals<sup>4-6,8-11</sup>

## Up to 1 full year of pain relief with just 1 simple, safe treatment

By targeting inflammatory cells in the joint, tin-117m provides local, durable pain relief—and reduces the drivers of disease progression<sup>8</sup>

Preclinical studies of tin-117m in rats<sup>8</sup>

### PRECLINICAL STUDIES OF TIN-117M IN RATS,— POWERFUL EVIDENCE OF DISEASE MODIFICATION<sup>8,9</sup>

#### REDUCED SYNOVITIS

Significant reduction  
in synovitis score

73%

Results v. controls: Low dose tin-117m Week 1. Measured by degree of mononuclear cell infiltration.

#### PROTECTED CARTILAGE

Significant reduction in  
cartilage degeneration

65%

Results vs. controls: Low dose tin-117m Week 1. Measured by chondrocyte and proteoglycan loss in micrometers.

#### REDUCED OSTEOPHYTES

Significant reduction  
in osteophyte growth

80%

Results vs. controls: Low dose tin-117m Week 1. Scored by measuring by osteophyte thickness in micrometers.

### Clinical trials of Synovetin OA in dogs with elbow OA<sup>4-6</sup>

- Demonstrated the ability of tin-117m to alleviate symptoms—well beyond its active life in the joint
  - A solid indicator of the impact on joint disease
- Targeting of synovial inflammatory cells offers extended clinical benefits

RESULTS INDICATE A POSSIBLE  
EFFECT ON THE COURSE OF THE  
DISEASE RATHER THAN A TRANSIENT  
ANTI-INFLAMMATORY RESPONSE<sup>4-6,8</sup>



Improvements increased  
steadily up to 9-months  
post-treatment



Improvements persisted  
through the end of  
the study (12-months)

*“...This review substantiates [tin-117m] as a transformative veterinary therapy, bridging preclinical insights with clinical outcomes that strongly support a positive disease-modifying mechanism.”*

— Bendele A, Doer CA, Gonzales GR, et al.  
Front. Vet. Sci. 2025;12:1-13

### Many different dogs can benefit from Synovetin OA

#### YOUNG DOGS WITH EARLY OA



Synovetin OA can manage  
the inflammatory process  
that drives OA pain and  
disease progression

#### DOGS WITH CHRONIC OA



Synovetin OA offers a  
local alternative to  
systemic NSAIDs

#### DOGS POST SURGERY TO ADDRESS OA



After surgical interventions,  
Synovetin OA can help  
manage the arthritis-inducing  
inflammation in the joint.

### Numerous benefits for dogs, dog parents—and you



#### FOR DOGS

- Up to 1 full year of safe, non-systemic relief for a better quality of life
- Works at the source of the disease; doesn't just mask pain signals, for a more effective solution
- Minimally invasive with quick return to activity so they get back to living fast



#### FOR DOG PARENTS

- A convenient option with no need to remember and administer multiple daily meds
- Peace of mind from proven effectiveness and safety demonstrated in clinical studies and real-world use in 1000s of dogs
- Quick recovery time lets them get back to enjoying the companionship of their pet



#### FOR YOU

- An easy, simple, fast procedure with same-day release
- Uniquely targeted to treat inflammation that drives pain and progression
- Highly profitable for your practice
- Offering specialized, progressive medicine is a practice differentiator

Visit [synovetin.com](https://synovetin.com) to learn more about  
the benefits of Synovetin OA.

Great news for dog parents—  
Synovetin OA is covered by pet insurance plans!

# Only Synovetin OA is designed to reduce the inflammation driving OA pain and progression

For symptom relief and potential structural preservation<sup>4-6,8-11</sup>



Proven year-long relief with 1 easy treatment<sup>4</sup>



Targets the root cause of pain and cartilage loss<sup>4-6</sup>



Zero systemic side effects<sup>7</sup>



Disease modifying mechanism of action<sup>8\*</sup>



Can reduce or eliminate OA drugs in majority of cases<sup>12</sup>



Consider earlier intervention with Synovetin OA to mitigate inflammation—the primary driver of OA joint pain—cartilage degradation, and loss of function over time.

Read more about Synovetin OA at [synovetin.com](https://synovetin.com).

**References:** 1. Romer FW, Guermazi A, Felson DT, et al. *Ann Rheum Dis*. 2011;70(10):1804-1809. doi: 10.1136/ard.2011.150243. 2. Sellam J, Berenbaum F. *Nat Rev Rheumatol*. 2010; 6:625-635. <https://doi.org/10.1038/nrrheum.2010.159> PMID: 20924410. 3. Scanzello CR, Umoh E, Pessler F, et al. *Osteoarthritis Cartilage*. 2009; 17: 1040-1048. <https://doi.org/10.1016/j.joca.2009.02.011> PMID: 192892341. 4. Aulakh KS, Lopez MJ, Hudson C, et al. *Vet Med (Auckl)*. 2021. Jun 4;12:117-128. doi: 10.2147/VMRR.S295309. PMID: 34113552; PMCID: PMC8187093. 5. Donecker J, Fabiani M, Gaschen L, Aulakh KS. *PLoS One*. 2021. Jul 19;16(7):e0254613. doi: 10.1371/journal.pone.0254613. PMID: 34280212; PMCID: PMC8289027. 6. Donecker J, Lattimer JC, Gaschen L, Aulakh KS. *Vet Med (Auckl)*. 2021. Dec 17;12:325-335. doi: 10.2147/VMRR.S345144. PMID: 34950571; PMCID: PMC8691448. 7. Lattimer JC, Selting KA, Lunceford JM, et al. *Vet Radiol Ultrasound*. 2019. Sep;60(5):567-574. doi: 10.1111/vru.12757. Epub 2019 Jun 2. PMID: 31155782. 8. Bendele A, Doerr CA, Gonzales GR, et al. Evidence of osteoarthritis disease modification with a Sn-117m microparticle device: a review and validation in mammalian models. *Front. Vet. Sci.* 2-25;12:1-13 doi: 10.3389/fvets.2025.1621296. 9. Doerr C, Bendele A, Simon J, et al. *J Nucl Med*. 2016;57(suppl) 2:323. 10. Doerr C, Bendele A, Simon J, et al. Poster presented at the Society of Nuclear Medicine & Molecular Imaging Annual Conference. San Diego, CA. 2016. 11. Data on File. Pathology Report. Boulder BioPATH, Inc.; Boulder, CO. 12. Data on File. March 2026 Treating Veterinarian Survey. Exubriion Therapeutics, Inc.

\*As demonstrated in preclinical published studies of induced osteoarthritis in rodent models.

Synovetin OA® is marketed by:

**EXUBRIION**  
THERAPEUTICS

© 2026 Exubriion Therapeutics, Inc. All Rights Reserved.  
Printed in USA. April 2026 EXN-SYN-252

**Synovetin OA**  
Long-lasting Relief